Here’s What Analysts Think About Arcus Biosciences (RCUS)

Core Viewpoint - Arcus Biosciences, Inc. (NYSE:RCUS) is experiencing mixed analyst ratings, with recent downgrades and upgrades reflecting uncertainty in its product differentiation and upcoming clinical data readouts [1][2]. Analyst Ratings - Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight, lowering the price target from $30 to $23 due to unclear differentiation for Welireg and potential negative impacts from upcoming data readouts [1]. - Bank of America Securities maintained a Hold rating with a price target of $26 [2]. - Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $16 to $28, highlighting the potential of the company's lead asset, casdatifan [2]. Product Development - Casdatifan is a selective HIF-2alpha inhibitor being developed for advanced clear cell renal cell carcinoma, with an estimated total addressable market of approximately 17,400 patients in the US/EU and projected risk-adjusted peak sales of about $1.7 billion [3]. - Phase 1 results for the ARC-20 trial showed overall response rates of 31% for the mono regimen and 46% for the combination regimen, with expectations for further improvement as the trial matures [3]. Company Overview - Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing immunotherapies, competing in the biotechnology and pharmaceutical sectors [4].